Table 2:
Characteristics of inflammatory bowel disease (IBD) subjects with meningitis and matched IBD controls in the Quintiles IMS Legacy PharMetrics Adjudicated Claims Database between January 2001 and June 2016
| Meningitis IBD Cases | Non-Meningitis IBD Controls | p-value | |
|---|---|---|---|
| N | 162 | 281 | |
| % Female | 62 | 63 | 0.92 |
| % Crohn’s Disease Median current age in years (IQR) |
53 55 (44–63) |
52 57 (47–64) |
0.92 0.10 |
| Region | <0.01 | ||
| % East | 30 | 8 | |
| % Midwest | 22 | 30 | |
| % South | 35 | 31 | |
| % West | 13 | 31 | |
| Charlson Comorbidity Index | <0.01 | ||
| % 0 | 62 | 82 | |
| % 1 | 23 | 15 | |
| % ≥2 | 15 | 3 | |
| IBD Medication Exposure | |||
| % 5-ASA* | 23 | 34 | 0.02 |
| % Thiopurine | 11 | 10 | 0.75 |
| % Anti-TNF# | 10 | 8 | 0.60 |
| % Systemic Corticosteroids^ | 15 | 8 | 0.02 |
IQR: Inter-Quartile Range
*
5-Aminosalicylates: oral formulations only
#
TNF: Anti-Tumor Necrosis Factor-α
^
Defined as ≥ 2 week course of any oral systemic formulation